This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Beauty Health Company (SKIN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Beauty Health (SKIN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and +1.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Fast-paced Mover Beauty Health (SKIN) Is a Great Choice for Value Investors
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Beauty Health (SKIN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Despite Fast-paced Momentum, Beauty Health (SKIN) Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Beauty Health (SKIN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Beauty Health (SKIN) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Explore Beauty Health's (SKIN) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Beauty Health (SKIN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Beauty Health (SKIN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beauty Health (SKIN) delivered earnings and revenue surprises of 38.46% and 10.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
BrightSpring Health Services, Inc. (BTSG) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BrightSpring Health Services, Inc. (BTSG) delivered earnings and revenue surprises of 137.50% and 5.44%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Beauty Health (SKIN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Beauty Health (SKIN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Beauty Health Company (SKIN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beauty Health (SKIN) delivered earnings and revenue surprises of 20% and 8.61%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 250% and 3.96%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 23.57% and 0.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Beauty Health (SKIN) International Revenue Performance Explored
by Zacks Equity Research
Examine Beauty Health's (SKIN) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
The Beauty Health Company (SKIN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beauty Health (SKIN) delivered earnings and revenue surprises of -25% and 1.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CoDiagnostics (CODX) delivered earnings and revenue surprises of 3.03% and 60.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, Beauty Health (SKIN) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Beauty Health (SKIN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ModivCare (MODV) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -103.70% and 0.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What Key Metrics Tell Us About Beauty Health (SKIN) Q1 Earnings
by Zacks Equity Research
The headline numbers for Beauty Health (SKIN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beauty Health (SKIN) delivered earnings and revenue surprises of 28.57% and 1.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of -2.52% and 3%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, The Beauty Health Company (SKIN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for The Beauty Health Company (SKIN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 14.29% and 10.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 20.83% and 6.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Cencora (COR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cencora (COR) delivered earnings and revenue surprises of 14.69% and 5%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for The Beauty Health Company (SKIN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.